JP2006501215A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501215A5
JP2006501215A5 JP2004527226A JP2004527226A JP2006501215A5 JP 2006501215 A5 JP2006501215 A5 JP 2006501215A5 JP 2004527226 A JP2004527226 A JP 2004527226A JP 2004527226 A JP2004527226 A JP 2004527226A JP 2006501215 A5 JP2006501215 A5 JP 2006501215A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
treating
rheumatoid arthritis
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004527226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003613 external-priority patent/WO2004014892A1/en
Publication of JP2006501215A publication Critical patent/JP2006501215A/ja
Publication of JP2006501215A5 publication Critical patent/JP2006501215A5/ja
Pending legal-status Critical Current

Links

JP2004527226A 2002-08-13 2003-08-03 マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 Pending JP2006501215A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40304002P 2002-08-13 2002-08-13
PCT/IB2003/003613 WO2004014892A1 (en) 2002-08-13 2003-08-03 Monocyclic derivatives as matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
JP2006501215A JP2006501215A (ja) 2006-01-12
JP2006501215A5 true JP2006501215A5 (https=) 2006-09-14

Family

ID=31715927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004527226A Pending JP2006501215A (ja) 2002-08-13 2003-08-03 マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体

Country Status (8)

Country Link
US (1) US7132424B2 (https=)
EP (1) EP1537098A1 (https=)
JP (1) JP2006501215A (https=)
AU (1) AU2003253176A1 (https=)
BR (1) BR0313459A (https=)
CA (1) CA2494014A1 (https=)
MX (1) MXPA05001603A (https=)
WO (1) WO2004014892A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213233A (pt) 2001-10-12 2005-01-04 Warner Lambert Co Alcinos inibidores de metaloproteinase de matriz
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2934539B1 (en) * 2012-12-20 2019-03-27 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
US9580396B2 (en) 2012-12-21 2017-02-28 Merck Sharp & Dohme Corp. C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN120981454A (zh) * 2023-03-21 2025-11-18 (株)倍宝尊 mGluR5和HDAC6的双调节剂及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2650223A (en) * 1950-08-08 1953-08-25 Abbott Lab 2,5-diketopiperazines
DE1029001B (de) * 1956-06-30 1958-04-30 Basf Ag Verfahren zur Herstellung von basisch substituierten Derivaten des Pyridazinons-(3)
DE3825468A1 (de) * 1988-07-27 1990-02-01 Basf Ag 5-amino-6-pyridazonderivate, verfahren zu ihrer herstellung und sie enthaltende herbizide mittel
US5425289A (en) 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
EP0541042A1 (de) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
HN2000000137A (es) * 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
CN1501937A (zh) * 2000-10-26 2004-06-02 �Ʒ� 螺-嘧啶-2,4,6-三酮金属蛋白酶抑制剂
HUP0302337A3 (en) 2000-10-26 2004-01-28 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
BR0207865A (pt) * 2001-02-14 2004-03-23 Warner Lambert Co Benzotiadiazinas inibidores de metaloproteinases de matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
CA2433778A1 (en) 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
WO2002064571A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
SV2003001289A (es) 2001-10-12 2003-06-24 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
BR0213233A (pt) 2001-10-12 2005-01-04 Warner Lambert Co Alcinos inibidores de metaloproteinase de matriz
US6933298B2 (en) 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
US6700540B2 (en) * 2002-02-14 2004-03-02 Ericsson, Inc. Antennas having multiple resonant frequency bands and wireless terminals incorporating the same
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2002249275A1 (en) 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US20040006077A1 (en) 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2002333256A1 (en) 2002-06-25 2004-01-06 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Similar Documents

Publication Publication Date Title
JP2006501215A5 (https=)
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
EP2049710A4 (en) MASTER ELECTRODE AND METHOD OF MANUFACTURING THEREOF
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
EP1857425A4 (en) PIEZOELECTRIC CERAMIC COMPOSITION AND MANUFACTURING METHOD THEREFOR
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
JP2004500380A5 (https=)
FR2895406B1 (fr) Procede pour la fabrication de 2,3-dimethylbut-1-ene
JP2005532458A5 (https=)
JP2003284553A5 (https=)
FR2854078B1 (fr) Procede de fabrication d'une composition therapeutique immuno-stimulante.
EP1879013A4 (en) METHOD FOR CONSTRUCTING SELF-VULGATED DRUG ORMULATIONS
FR2890959B1 (fr) Procede de preparation d'une composition de platre.
EP1883628A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF 3,5-DIETHYL-1,2-DIHYDRO-1-PHENYL-2-PROPYLPYRIDINE
FR2890654B1 (fr) Procede de preparation d'une composition humique artificielle, et applications
JP2003501382A5 (https=)
FR2888843B1 (fr) Procede de preparation d'un diarylanthracene.
BRPI0410638A (pt) derivados de azitromicina
FR2885137B1 (fr) Procede de desulfuration d'essences olefiniques
EP1949264A4 (en) APPLICATION INTER WORKING
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
EP1959001A4 (en) Hydrorefining method
FR2892012B1 (fr) Procede d'epilation
TH2682C3 (th) กระบวนการผลิตหอยอนามัย
TH2682A3 (th) กระบวนการผลิตหอยอนามัย